European Heart Journal Advance Access published online on August 6, 2007
European Heart Journal, doi:10.1093/eurheartj/ehm328
Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia
1 Department of Cardiology, University Medical Center Groningen; University of Groningen; PO Box 30.001; 9700RB Groningen; The Netherlands
2 Stavanger University Hospital, Stavanger, Norway
3 University Hospital Beaujon, Clichy, France
4 Deventer Hospital, Deventer, The Netherlands
5 Amgen Inc, Thousand Oaks, CA, USA
6 Amgen Limited, Cambridge, UK
7 University of Hull, Castle Hill Hospital, Hull, UK
8 Military Hospital, Wroclaw, Poland
Received 12 April 2007; revised 4 July 2007; accepted 6 July 2007.
* Corresponding author. Tel: +31 50 3612355; fax: +31 50 3614391. E-mail address: d.j.van.veldhuisen{at}thorax.umcg.nl
Aims: Anaemia is common in chronic heart failure (CHF) and associated with worse outcome. This randomized, double-blind, placebo-controlled study evaluated the effect of two darbepoetin alfa dosing regimens on haemoglobin (Hb) rate of rise and clinical effects in patients with CHF and anaemia.
Methods and results: Patients with CHF (
3 months), left ventricular ejection fraction (LVEF) 
40%, and Hb 9.0 to 12.5 g/dL received darbepoetin alfa subcutaneously every 2 weeks for 26 weeks at a starting weight-adjusted dose of 0.75 mcg/kg (n = 56) or a fixed dose of 50 mcg (n = 54), or placebo (n = 55), to gradually achieve and maintain a target Hb of 14.0 ± 1.0 g/dL. Endpoints included rate of Hb rise per week during titration, safety, and changes in 6 min walk distance, New York Heart Association (NYHA) class, LVEF, and quality of life. Most subjects were NYHA class II–III. Mean (SD) age was 71 (11) years, LVEF was 28 (9), and Hb 11.5 (0.7) g/dL. Rate of Hb rise was equivalent between darbepoetin alfa weight-based (+1.87 ± 1.36 g/dL) and fixed dosing (+1.64 ± 0.98 g/dL) groups, vs. + 0.07 ± 1.08 g/dL in the placebo group. Mean Hb concentrations by week 27 were 13.4 and 13.2 g/dL, in the weight-based and fixed dosing groups, respectively. There were non-significant improvements in the combined darbepoetin alfa group vs. placebo for 6 min walk distance (P = 0.074) and Patient’s Global Assessment score (P = 0.057). There was a significant improvement in Kansas City Cardiomyopathy Questionnaire total symptom score (8.2 vs. 1.5 points; P = 0.027) but no change in NYHA class, LVEF, and Minnesota Living With Heart Failure Questionnaire score. Six treatment-unrelated deaths occurred in the 110 darbepoetin alfa treated patients, and none in the 55 placebo treated patients. Other adverse events were similar between groups.
Conclusion: In this study of patients with CHF and anaemia, treatment with darbepoetin alfa raised Hb using different dosing regimens. Darbepoetin alfa improved some quality of life indices, but its safety requires further exploration. Larger trials are needed to determine the effects on long-term morbidity and mortality.
Key Words: Anaemia • Heart failure • Exercise • Haemoglobin • Trials
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. van der Meer and D. J van Veldhuisen Anaemia and renal dysfunction in chronic heart failure Heart, November 1, 2009; 95(21): 1808 - 1812. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Klapholz, W. T. Abraham, J. K. Ghali, P. Ponikowski, S. D. Anker, B. Knusel, Y. Sun, S. M. Wasserman, and D. J. van Veldhuisen The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure Eur J Heart Fail, November 1, 2009; 11(11): 1071 - 1077. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Pascual-Figal, J. C. Bonaque, B. Redondo, C. Caro, S. Manzano-Fernandez, J. Sanchez-Mas, I. P. Garrido, and M. Valdes Red blood cell distribution width predicts long-term outcome regardless of anaemia status in acute heart failure patients Eur J Heart Fail, September 1, 2009; 11(9): 840 - 846. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Besarab, W. H. Horl, and D. Silverberg Iron Metabolism, Iron Deficiency, Thrombocytosis, and the Cardiorenal Anemia Syndrome Oncologist, September 1, 2009; 14(suppl_1): 22 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P van der Meer, H F Groenveld, J L Januzzi Jr, and D J van Veldhuisen Erythropoietin treatment in patients with chronic heart failure: a meta-analysis Heart, August 15, 2009; 95(16): 1309 - 1314. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J.V. McMurray, I. S. Anand, R. Diaz, A. P. Maggioni, C. O'Connor, M. A. Pfeffer, K. R. Polu, S. D. Solomon, Y. Sun, K. Swedberg, et al. Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial Eur J Heart Fail, August 1, 2009; 11(8): 795 - 801. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B P Geisler, R M van Dam, G S Gazelle, and A Goehler Risk of bias in meta-analysis on erythropoietin-stimulating agents in heart failure Heart, August 1, 2009; 95(15): 1278 - 1279. [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Anker, A. Voors, D. Okonko, A. L. Clark, M. K. James, S. von Haehling, J. Kjekshus, P. Ponikowski, K. Dickstein, and for the OPTIMAAL Investigators Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: data from the OPTIMAAL trial Eur. Heart J., June 1, 2009; 30(11): 1331 - 1339. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G.F. Cleland, A. P. Coletta, A. L. Clark, and D. Cullington Clinical trials update from the American College of Cardiology 2009: ADMIRE-HF, PRIMA, STICH, REVERSE, IRIS, partial ventricular support, FIX-HF-5, vagal stimulation, REVIVAL-3, pre-RELAX-AHF, ACTIVE-A, HF-ACTION, JUPITER, AURORA, and OMEGA Eur J Heart Fail, June 1, 2009; 11(6): 622 - 630. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Gao and W. J. Koch Is erythropoietin behind maladaptive anemic heart failure? Am J Physiol Heart Circ Physiol, March 1, 2009; 296(3): H559 - H560. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kazory and E. A. Ross Anemia: the point of convergence or divergence for kidney disease and heart failure? J. Am. Coll. Cardiol., February 24, 2009; 53(8): 639 - 647. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. D. Pagourelias, C. Koumaras, A. I. Kakafika, K. Tziomalos, P. G. Zorou, V. G. Athyros, and A. Karagiannis Cardiorenal Anemia Syndrome: Do Erythropoietin and Iron Therapy Have a Place in the Treatment of Heart Failure? Angiology, February 1, 2009; 60(1): 74 - 81. [Abstract] [PDF]
|
|
|
|
 |
|
 S. D. Anker and R. Toto Future perspectives on treatment with erythropoiesis-stimulating agents in high-risk patients NDT Plus, January 1, 2009; 2(suppl_1): i3 - i8. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Silverberg, D. Wexler, A. Iaina, and D. Schwartz The Role of Correction of Anemia in Patients With Congestive Heart Failure Associated with Chronic Kidney Failure Journal of Pharmacy Practice, December 1, 2008; 21(6): 420 - 423. [Abstract] [PDF]
|
|
|
|
|
|
S. Rastogi, M. Imai, V. G. Sharov, S. Mishra, and H. N. Sabbah Darbepoetin-{alpha} prevents progressive left ventricular dysfunction and remodeling in nonanemic dogs with heart failure Am J Physiol Heart Circ Physiol, December 1, 2008; 295(6): H2475 - H2482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.H. W. Tang and G. S. Francis The Year in Heart Failure J. Am. Coll. Cardiol., November 11, 2008; 52(20): 1671 - 1678. [Full Text] [PDF]
|
|
|
|
|
|
P. van der Meer, J. L. Januzzi, and D. J. van Veldhuisen Erythropoietin, haemoglobin, heart failure, and mortality: reply Eur. Heart J., November 1, 2008; 29(21): 2695 - 2696. [Full Text] [PDF]
|
|
|
|
|
|
Authors/Task Force Members, K. Dickstein, A. Cohen-Solal, G. Filippatos, J. J.V. McMurray, P. Ponikowski, P. A. Poole-Wilson, A. Stromberg, D. J. van Veldhuisen, D. Atar, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) Eur. Heart J., October 1, 2008; 29(19): 2388 - 2442. [Full Text] [PDF]
|
|
|
|
|
|
K. Dickstein, A. Cohen-Solal, G. Filippatos, J. J.V. McMurray, P. Ponikowski, P. A. Poole-Wilson, A. Stromberg, D. J. van Veldhuisen, D. Atar, A. W. Hoes, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) Eur J Heart Fail, October 1, 2008; 10(10): 933 - 989. [Full Text] [PDF]
|
|
|
|
|
|
H. F. Groenveld, J. L. Januzzi, K. Damman, J. van Wijngaarden, H. L. Hillege, D. J. van Veldhuisen, and P. van der Meer Anemia and Mortality in Heart Failure Patients: A Systematic Review and Meta-Analysis J. Am. Coll. Cardiol., September 2, 2008; 52(10): 818 - 827. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Silverberg, D. Wexlerb, A. Iaina, and D. Schwartz The role of correction of anaemia in patients with congestive heart failure: A short review Eur J Heart Fail, September 1, 2008; 10(9): 819 - 823. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. S. Anand Anemia and Chronic Heart Failure: Implications and Treatment Options J. Am. Coll. Cardiol., August 12, 2008; 52(7): 501 - 511. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. van Veldhuisen, S. M. Wasserman, and N. Baker Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regiments of darbepoetin alfa in patients with heart failure and anaemia: reply Eur. Heart J., February 2, 2008; 29(4): 566 - 567. [Full Text] [PDF]
|
|
|
|
|
|
P. Leszek and M. Kruszewski Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia Eur. Heart J., February 2, 2008; 29(4): 565 - 566. [Full Text] [PDF]
|
|
|
|
|
|
N. F. Murphy and K. McDonald Treatment of anaemia in chronic heart failure optimal approach still unclear Eur. Heart J., September 2, 2007; 28(18): 2185 - 2187. [Full Text] [PDF]
|
|